RU2012136824A - Способы лечения вирусной инфекции гепатита с - Google Patents
Способы лечения вирусной инфекции гепатита с Download PDFInfo
- Publication number
- RU2012136824A RU2012136824A RU2012136824/15A RU2012136824A RU2012136824A RU 2012136824 A RU2012136824 A RU 2012136824A RU 2012136824/15 A RU2012136824/15 A RU 2012136824/15A RU 2012136824 A RU2012136824 A RU 2012136824A RU 2012136824 A RU2012136824 A RU 2012136824A
- Authority
- RU
- Russia
- Prior art keywords
- administered
- patient
- amount
- approximately
- increased
- Prior art date
Links
- 208000036142 Viral infection Diseases 0.000 title 1
- 208000006454 hepatitis Diseases 0.000 title 1
- 231100000283 hepatitis Toxicity 0.000 title 1
- 230000009385 viral infection Effects 0.000 title 1
- 108010050904 Interferons Proteins 0.000 claims abstract 9
- 102000014150 Interferons Human genes 0.000 claims abstract 9
- 229940079322 interferon Drugs 0.000 claims abstract 9
- 210000002381 plasma Anatomy 0.000 claims abstract 4
- 102100040018 Interferon alpha-2 Human genes 0.000 claims abstract 3
- 108010079944 Interferon-alpha2b Proteins 0.000 claims abstract 3
- IWUCXVSUMQZMFG-AFCXAGJDSA-N Ribavirin Chemical compound N1=C(C(=O)N)N=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 IWUCXVSUMQZMFG-AFCXAGJDSA-N 0.000 claims abstract 3
- 229940079593 drug Drugs 0.000 claims abstract 3
- 239000003814 drug Substances 0.000 claims abstract 3
- 229960000329 ribavirin Drugs 0.000 claims abstract 3
- HZCAHMRRMINHDJ-DBRKOABJSA-N ribavirin Natural products O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1N=CN=C1 HZCAHMRRMINHDJ-DBRKOABJSA-N 0.000 claims abstract 3
- 210000004185 liver Anatomy 0.000 claims abstract 2
- 230000036470 plasma concentration Effects 0.000 claims abstract 2
- 239000000203 mixture Substances 0.000 claims 4
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4535—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a heterocyclic ring having sulfur as a ring hetero atom, e.g. pizotifen
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/7056—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing five-membered rings with nitrogen as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Molecular Biology (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Virology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Oncology (AREA)
- Gastroenterology & Hepatology (AREA)
- Communicable Diseases (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (9)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US29964310P | 2010-01-29 | 2010-01-29 | |
| US61/299,643 | 2010-01-29 | ||
| US30850610P | 2010-02-26 | 2010-02-26 | |
| US61/308,506 | 2010-02-26 | ||
| US30911710P | 2010-03-01 | 2010-03-01 | |
| US61/309,117 | 2010-03-01 | ||
| US32439510P | 2010-04-15 | 2010-04-15 | |
| US61/324,395 | 2010-04-15 | ||
| PCT/US2011/022854 WO2011094489A1 (en) | 2010-01-29 | 2011-01-28 | Therapies for treating hepatitis c virus infection |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| RU2012136824A true RU2012136824A (ru) | 2014-03-10 |
Family
ID=43901208
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2012136824/15A RU2012136824A (ru) | 2010-01-29 | 2011-01-28 | Способы лечения вирусной инфекции гепатита с |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US20130034522A1 (enExample) |
| EP (1) | EP2528605A1 (enExample) |
| JP (1) | JP2013518124A (enExample) |
| KR (1) | KR20120139699A (enExample) |
| CN (1) | CN102844030A (enExample) |
| AU (1) | AU2011210795A1 (enExample) |
| CA (1) | CA2788348A1 (enExample) |
| IL (1) | IL220937A0 (enExample) |
| MX (1) | MX2012008652A (enExample) |
| RU (1) | RU2012136824A (enExample) |
| SG (1) | SG182589A1 (enExample) |
| TW (1) | TW201130502A (enExample) |
| WO (1) | WO2011094489A1 (enExample) |
| ZA (1) | ZA201205547B (enExample) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8399615B2 (en) | 2005-08-19 | 2013-03-19 | Vertex Pharmaceuticals Incorporated | Processes and intermediates |
| JP2013531011A (ja) * | 2010-06-28 | 2013-08-01 | バーテックス ファーマシューティカルズ インコーポレイテッド | フラビウイルス感染の処置または予防のための化合物および方法 |
| WO2012040127A1 (en) | 2010-09-22 | 2012-03-29 | Alios Biopharma, Inc. | Substituted nucleotide analogs |
| US8466159B2 (en) | 2011-10-21 | 2013-06-18 | Abbvie Inc. | Methods for treating HCV |
| US8492386B2 (en) | 2011-10-21 | 2013-07-23 | Abbvie Inc. | Methods for treating HCV |
| CN104023726A (zh) | 2011-10-21 | 2014-09-03 | 艾伯维公司 | 用于治疗hcv的一种或多种daa的联合治疗(例如，与abt-072或abt-333) |
| DE112012003510T5 (de) | 2011-10-21 | 2015-03-19 | Abbvie Inc. | Verfahren zur Behandlung von HCV umfassend mindestens zwei direkt wirkende antivirale Wirkstoffe, Ribavirin aber nicht Interferon |
| EP2794630A4 (en) | 2011-12-22 | 2015-04-01 | Alios Biopharma Inc | SUBSTITUTED PHOSPHORTHIOAT NUCLEOTIDE ANALOGUE |
| WO2013142159A1 (en) * | 2012-03-21 | 2013-09-26 | Alios Biopharma, Inc. | Pharmaceutical combinations comprising a thionucleotide analog |
| NZ631601A (en) | 2012-03-21 | 2016-06-24 | Alios Biopharma Inc | Solid forms of a thiophosphoramidate nucleotide prodrug |
| NZ630805A (en) | 2012-03-22 | 2016-01-29 | Alios Biopharma Inc | Pharmaceutical combinations comprising a thionucleotide analog |
| JP7129703B2 (ja) | 2016-04-28 | 2022-09-02 | エモリー ユニバーシティー | アルキン含有ヌクレオチド及びヌクレオシド治療組成物並びにそれらに関連した使用 |
Family Cites Families (47)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE69334250D1 (de) | 1992-12-29 | 2009-01-29 | Abbott Lab | Verfahren und Intermediate zur Herstellung von retroviralen Proteasehemmern |
| IL110752A (en) | 1993-09-13 | 2000-07-26 | Abbott Lab | Liquid semi-solid or solid pharmaceutical composition for an HIV protease inhibitor |
| US5559158A (en) | 1993-10-01 | 1996-09-24 | Abbott Laboratories | Pharmaceutical composition |
| IL111991A (en) | 1994-01-28 | 2000-07-26 | Abbott Lab | Liquid pharmaceutical composition of HIV protease inhibitors in organic solvent |
| US6037157A (en) | 1995-06-29 | 2000-03-14 | Abbott Laboratories | Method for improving pharmacokinetics |
| US5807876A (en) | 1996-04-23 | 1998-09-15 | Vertex Pharmaceuticals Incorporated | Inhibitors of IMPDH enzyme |
| US6054472A (en) | 1996-04-23 | 2000-04-25 | Vertex Pharmaceuticals, Incorporated | Inhibitors of IMPDH enzyme |
| PL192628B1 (pl) | 1996-04-23 | 2006-11-30 | Vertex Pharma | Pochodne mocznika, kompozycje farmaceutyczne i zastosowanie związku i kompozycji |
| ATE244717T1 (de) | 1997-03-14 | 2003-07-15 | Vertex Pharma | Inhibitoren des impdh-enzyms |
| US20040058982A1 (en) | 1999-02-17 | 2004-03-25 | Bioavailability System, Llc | Pharmaceutical compositions |
| CZ301802B6 (cs) | 1999-03-19 | 2010-06-30 | Vertex Pharmaceuticals Incorporated | Deriváty mocoviny jako inhibitory IMPDH a farmaceutické prostredky s jejich obsahem |
| AU2001268885A1 (en) | 2000-06-28 | 2002-01-08 | National Research Council Of Canada | Helicobacter dd-heptosyltransferase |
| SV2003000617A (es) | 2000-08-31 | 2003-01-13 | Lilly Co Eli | Inhibidores de la proteasa peptidomimetica ref. x-14912m |
| MXPA03006514A (es) | 2001-01-22 | 2004-12-02 | Merck & Co Inc | Derivados de nucleosidos como inhibidores de polimerasa de acido ribonucleico viral dependiente de acido ribonucleico. |
| EP2363396A1 (en) | 2001-06-11 | 2011-09-07 | Virochem Pharma Inc. | Thiophene derivatives as antiviral agents for flavivirus infection |
| CA2369711A1 (en) | 2002-01-30 | 2003-07-30 | Boehringer Ingelheim (Canada) Ltd. | Macrocyclic peptides active against the hepatitis c virus |
| US6642204B2 (en) | 2002-02-01 | 2003-11-04 | Boehringer Ingelheim International Gmbh | Hepatitis C inhibitor tri-peptides |
| US7091184B2 (en) | 2002-02-01 | 2006-08-15 | Boehringer Ingelheim International Gmbh | Hepatitis C inhibitor tri-peptides |
| CA2369970A1 (en) | 2002-02-01 | 2003-08-01 | Boehringer Ingelheim (Canada) Ltd. | Hepatitis c inhibitor tri-peptides |
| EP1545545A4 (en) | 2002-08-01 | 2008-09-03 | Pharmasset Inc | COMPOUNDS WITH THE BICYCLO 4.2.1 NONAN SYSTEM FOR THE TREATMENT OF FLAVIVIRIDAE / I INFECTIONS |
| CA2413705A1 (en) | 2002-12-06 | 2004-06-06 | Raul Altman | Use of meloxicam in combination with an antiplatelet agent for treatment of acute coronary syndrome and related conditions |
| US7098231B2 (en) | 2003-01-22 | 2006-08-29 | Boehringer Ingelheim International Gmbh | Viral polymerase inhibitors |
| US7223785B2 (en) | 2003-01-22 | 2007-05-29 | Boehringer Ingelheim International Gmbh | Viral polymerase inhibitors |
| JP2006517960A (ja) | 2003-02-18 | 2006-08-03 | ファイザー インコーポレイテッド | Ｃ型肝炎ウイルスの阻害剤、それを使用する組成物および治療法 |
| DE602004029866D1 (de) | 2003-03-05 | 2010-12-16 | Boehringer Ingelheim Pharma | Peptidanaloga mit inhibitorischer wirkung auf hepatitis c |
| JP4550824B2 (ja) | 2003-03-05 | 2010-09-22 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | Ｃ型肝炎抑制化合物 |
| CL2004001161A1 (es) | 2003-05-21 | 2005-04-08 | Boehringer Ingelheim Int | Compuestos describe compuestos derivados de quinolina; composicion farmaceutica; y su uso para tratar una enfermedad causada por el virus de la hepatitis c. |
| WO2005018330A1 (en) | 2003-08-18 | 2005-03-03 | Pharmasset, Inc. | Dosing regimen for flaviviridae therapy |
| CA2538843A1 (en) | 2003-09-12 | 2005-03-24 | Vertex Pharmaceuticals Incorporated | Animal model for protease activity and liver damage |
| US6933760B2 (en) | 2003-09-19 | 2005-08-23 | Intel Corporation | Reference voltage generator for hysteresis circuit |
| EP1673385B1 (en) | 2003-09-22 | 2011-03-02 | Boehringer Ingelheim International GmbH | Macrocyclic peptides active against the hepatitis c virus |
| US7132504B2 (en) | 2003-11-12 | 2006-11-07 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| WO2005070955A1 (en) | 2004-01-21 | 2005-08-04 | Boehringer Ingelheim International Gmbh | Macrocyclic peptides active against the hepatitis c virus |
| US20050187192A1 (en) | 2004-02-20 | 2005-08-25 | Kucera Pharmaceutical Company | Phospholipids for the treatment of infection by togaviruses, herpes viruses and coronaviruses |
| CN1922174A (zh) | 2004-02-20 | 2007-02-28 | 贝林格尔·英格海姆国际有限公司 | 病毒聚合酶抑制剂 |
| US20050288333A1 (en) | 2004-06-08 | 2005-12-29 | Kem William R | Controlling angiogenesis with anabaseine analogs |
| MY141025A (en) | 2004-10-29 | 2010-02-25 | Vertex Pharma | Dose forms |
| EP1991229A2 (en) | 2006-02-27 | 2008-11-19 | Vertex Pharmaceuticals Incorporated | Co-crystals and pharmaceutical compositions comprising the same |
| JP2009531315A (ja) | 2006-03-16 | 2009-09-03 | バーテックス ファーマシューティカルズ インコーポレイテッド | 重水素化ｃ型肝炎プロテアーゼインヒビター |
| WO2007109605A2 (en) | 2006-03-20 | 2007-09-27 | Vertex Pharmaceuticals Incorporated | Pharmaceutical compositions |
| JP2009530415A (ja) | 2006-03-20 | 2009-08-27 | バーテックス ファーマシューティカルズ インコーポレイテッド | 医薬組成物 |
| SG176488A1 (en) * | 2006-11-15 | 2011-12-29 | Virochem Pharma Inc | Thiophene analogues for the treatment or prevention of flavivirus infections |
| MX2009006806A (es) | 2006-12-22 | 2009-08-27 | Vertex Pharma | Secado por rocio fluidizado. |
| EA200970806A1 (ru) | 2007-02-27 | 2010-08-30 | Вертекс Фармасьютикалз Инкорпорейтед | Сокристаллы и содержащие их фармацевтические композиции |
| EP2157974A1 (en) | 2007-05-21 | 2010-03-03 | Vertex Pharmceuticals Incorporated | Dose forms comprising vx- 950 and their dosage regimen |
| EP2170888B1 (en) * | 2007-06-29 | 2015-04-22 | Gilead Sciences, Inc. | Purine derivatives and their use as modulators of toll-like receptor 7 |
| WO2010002998A1 (en) * | 2008-07-03 | 2010-01-07 | Gilead Sciences, Inc. | 2,4,6-TRISUBSTITUTED PYRIDO (3,2-d) PYRIMIDINES USEFUL FOR TREATING VIRAL INFECTIONS |
-
2011
- 2011-01-28 AU AU2011210795A patent/AU2011210795A1/en not_active Abandoned
- 2011-01-28 KR KR1020127021714A patent/KR20120139699A/ko not_active Withdrawn
- 2011-01-28 CA CA2788348A patent/CA2788348A1/en not_active Abandoned
- 2011-01-28 TW TW100103512A patent/TW201130502A/zh unknown
- 2011-01-28 SG SG2012053120A patent/SG182589A1/en unknown
- 2011-01-28 JP JP2012551302A patent/JP2013518124A/ja active Pending
- 2011-01-28 CN CN2011800168308A patent/CN102844030A/zh active Pending
- 2011-01-28 WO PCT/US2011/022854 patent/WO2011094489A1/en not_active Ceased
- 2011-01-28 EP EP11703776A patent/EP2528605A1/en not_active Withdrawn
- 2011-01-28 RU RU2012136824/15A patent/RU2012136824A/ru not_active Application Discontinuation
- 2011-01-28 MX MX2012008652A patent/MX2012008652A/es active IP Right Grant
-
2012
- 2012-07-12 IL IL220937A patent/IL220937A0/en unknown
- 2012-07-23 ZA ZA2012/05547A patent/ZA201205547B/en unknown
- 2012-07-27 US US13/559,995 patent/US20130034522A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| JP2013518124A (ja) | 2013-05-20 |
| CN102844030A (zh) | 2012-12-26 |
| IL220937A0 (en) | 2012-09-24 |
| SG182589A1 (en) | 2012-08-30 |
| TW201130502A (en) | 2011-09-16 |
| MX2012008652A (es) | 2012-08-23 |
| ZA201205547B (en) | 2013-04-24 |
| CA2788348A1 (en) | 2011-08-04 |
| EP2528605A1 (en) | 2012-12-05 |
| US20130034522A1 (en) | 2013-02-07 |
| KR20120139699A (ko) | 2012-12-27 |
| WO2011094489A1 (en) | 2011-08-04 |
| AU2011210795A1 (en) | 2012-08-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2007105354A (ru) | Применение комбинации циклоспорина и пэгилированного интерферона для лечения гепатита с (hcv) | |
| RU2011127080A (ru) | Производное циклоспорина для применения в лечении заражения вирусом гепатита с и вич | |
| JP2011519364A5 (enExample) | ||
| NZ631155A (en) | Combination of two antivirals for treating hepatitis c | |
| JP2013518124A5 (enExample) | ||
| BG106906A (bg) | Пуринови производни | |
| JP2008518943A5 (enExample) | ||
| JP2014530874A5 (enExample) | ||
| EA201490903A1 (ru) | Композиции и способы лечения вирусного гепатита c | |
| MX2012008652A (es) | Terapias para tratar infeccion por virus de hepatitis c. | |
| RU2013148779A (ru) | Лечение инфекции вируса гепатита в по отдельности или в комбинации с вирусом гепатита дельта и родственных заболеваний печени | |
| NZ598465A (en) | Dosage regimens for hcv combination therapy comprising bi201335, interferon alpha and ribavirin | |
| NZ588655A (en) | Treatment of hepatitis c virus infections with telaprevir (vx-950) in patients non-responsive to treatment with pegylated interfer0n-alpha-2a/2b and ribavirin | |
| MX2010013522A (es) | Uso de telaprevir en combinacion con interferon pegilado y ribavirina para tratar el virus de la hepatitis c. | |
| RU2006107566A (ru) | Способ лечения вирусных инфекций | |
| JP2016153402A (ja) | Ｃ型肝炎ウイルス感染症の新規治療 | |
| Ferenci | Treatment of chronic hepatitis C–are interferons really necessary? | |
| RU2013129824A (ru) | Новое лечение инфекции вируса гепатита с | |
| RU2013148539A (ru) | Алиспоривир для лечения инфекции вируса гепатита с | |
| WO2011135743A1 (ja) | Ｃ型肝炎の予防及び／又は治療のための医薬 | |
| RU2014116988A (ru) | Алиспоривир для лечения инфекции, вызванной вирусом гепатита с | |
| US20150174194A1 (en) | Methods for treating liver transplant recipients | |
| RU2012109938A (ru) | Способ лечения вирусного гепатита с | |
| RU2013150344A (ru) | Лечение инфекции вируса гепатита алисповиром | |
| Sabbatani et al. | Overwhelming diffuse psoriasis during chronic HCV infection, after peginterferon-ribavirin treatment, supported by frequent resort to filgrastim rescue |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA92 | Acknowledgement of application withdrawn (lack of supplementary materials submitted) |
Effective date: 20150624 |